The Food and Drug Administration's (FDA's) approval of oral tyrosine kinase inhibitors, Capmatinib in 2020 and Tepotinib in 2021, for metastatic NSCLC with MET exon 14 skipping mutations, highlights the need to detect this variation among NSCLC [3]. This evidence concerns the gene MET and non-small cell lung carcinoma.